FY 2006 appropriation for effectiveness research
Executive Summary
House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...
You may also be interested in...
Rx Comparative Effectiveness Research Funds Included In HHS Approps Bill
Funding for prescription drug comparative effectiveness research is included in the HHS fiscal year 2005 appropriations bill reported to the full Senate Sept. 15
Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: